Lesniewski-Kmak, K ; Moiseenko, V ; Saunders, M...
Lesniewski-Kmak , K , Moiseenko , V , Saunders , M , Wasan , H , Argiles , G , Borg , C , Creemers , G , Fedyanin , M , Glynne-Jones , R , Pfeiffer , P , Punt , C , Stroyakovskiy , D , Ten Tije , A , Van de Wouw , A , Kanehisa , A , Fougeray , R , Busto , N L , Amellal , N & Van Cutsem , E 2018 , ' Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1) : Results of the primary analysis ' , Annals of Oncology , vol. 29 , no. 5 , pp. v108 . https://doi.org/10.1093/annonc/mdy149.021.  , 2018